s:**
- Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology
- Measure whether pharmacological HCN1 enha

V2, Crosslink

🧫

s:** - Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology - Measure whether pharmacological HCN1 enha

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-debate-2648b2f4b976

🧫 Experiment Protocol Falsificationproposed

SUMMARY

# s:** - Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology - Measure whether pharmacological HCN1 enha ## Background and Rationale This experiment investigates the specific role of HCN1 channels in entorhinal cortex layer II neurons and their contribution to Alzheimer's disease pathology progression. HCN1 (Hyperpolarization-activated Cyclic Nucleotide-gated channel 1) channels are critical for neuronal excitability and rhythmic activity, particul

METHODOLOGY NOTES

**Phase 1: Cell Culture Preparation (Days 1-7)** • Establish iPSC-derived entorhinal cortex layer II neurons from control and AD patient lines (n=6 each) • Generate HCN1 knockout cell lines using CRISPR/Cas9 with gRNAs targeting exons 2-3 of HCN1 • Validate knockout efficiency by qRT-PCR and Western blot (>95% reduction required) • Maintain cultures in Neurobasal-A medium with B27 supplement at 37°C, 5% CO2 **Phase 2: Pathology Induction and Treatment (Days 8-35)** • Treat cells with Aβ42 oligomers (1-5 μM) and tau K18 fibrils (100-500 nM) to induce AD-like pathology • Apply pharmacological treatments: ZD7288 (HCN1 blocker, 10-100 μM) and ivabradine (HCN1 enhancer, 1-10 μM) • Establish experimental groups: Control, AD pathology, AD+HCN1 KO, AD+ZD7288, AD+ivabradine • Monitor cell viability daily using MTT assay and live/dead staining **Phase 3: Molecular Analysis (Days 21, 28, 35)** • Collect samples for Western blot analysis of phospho-tau (AT8, PHF-1), total tau, Aβ levels • Perfor

▸Metadatasource: {'type': 'manual', 'source_name': 'debat

source	{'type': 'manual', 'source_name': 'debate_extraction', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.909748Z'}
summary	# s:** - Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology - Measure whether pharmacological HCN1 enha ## Background and Rationale This experiment inv
entities	{'genes': ['HCN1'], 'diseases': ["Alzheimer's Disease"]}
model_system	cell_line
_schema_version	1
experiment_type	falsification
primary_outcome	Comparative analysis of tau pathology development and neuronal survival in HCN1 knockout versus control entorhinal cortex layer II neurons following amyloid-beta and tau exposure.
methodology_notes	Phase 1: Cell Culture Preparation (Days 1-7) • Establish iPSC-derived entorhinal cortex layer II neurons from control and AD patient lines (n=6 each) • Generate HCN1 knockout cell lines using CRIS
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.909754', 'needs_review': True, 'extraction_notes': 'Backfilled from debate_extraction source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

533

Outgoing

489

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

s:** - Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology - Measure whether pharmacological HCN1 enha

derives from (15)

supports (5)

💬 Discussion